Sample prep engineered for liquid biopsy. nRichDX, based in Irvine, CA is an emerging leader in the liquid biopsy sample prep market, delivering significantly more analyte (cfDNA, ctDNA, cfTNA, cfRNA) than existing sample prep systems for molecular testing. The nRichDX liquid biopsy sample prep platform is the result of an intensive technology development effort that commenced in 2016. Being introduced in late 2018, the nRichDX system is a 510K-exempt, highly differentiated, universal sample prep system for the multi-billion dollar liquid biopsy and precision medicine markets. nRichDX solves one of precision medicine’s greatest problems - - inaccurate diagnostic results for up to 50% of liquid biopsy-based molecular diagnostic tests (NGS, PCR, Micro Array, etc.) due to a lack of target material. The nRichDX platform improves workflow, greatly enhances test sensitivity and produces consistently reliable test results while increasing revenue and reducing operational costs and complexity.